Ved skift til andre lægemiddelformer uanset type bør terapeutisk monitorering og dosisjusteringer finde sted for at sikre, at systemisk eksponering for tacrolimus opretholdes.
Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.